Abstract
Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptors agonist, has demonstrated efficacy in the treatment of patients with an acute exacerbation of schizophrenia in a 4-week, double-blind, placebo-controlled study. The aim of this 26-week open-label extension study was to evaluate the safety and effectiveness of ulotaront (25/50/75 mg/d) in patients who completed the initial 4-week study. Of the 193 4-week completers, 157 patients (81.3%) continued into the open-label extension study; 66.9% were completers. Among all extension phase patients, treatment with ulotaront was associated with minimal changes in body weight (mean [SD] change from double-blind baseline: −0.3 [3.7] kg), cholesterol (median change, −2.0 mg/dL), triglycerides (median, −5.0 mg/dL), and prolactin (female, median, −3.4 ng/mL; male, median, −2.7 ng/mL). Movement disorder scales showed no extrapyramidal effects. Twenty-six weeks of extension phase treatment was associated with a mean (95% CI) observed change from open-label baseline in the PANSS total score of −22.6 (−25.6, −19.6; effect size, 1.46), and a mean (95% CI) change in the CGI-Severity score of −1.0 (−1.2, −0.8; effect size, 1.07). Long-term treatment with the TAAR1 agonist ulotaront, in the daily dose range of 25–75 mg, was characterized by a relatively high completion rate, an adverse event profile notable for the absence of extrapyramidal-related adverse effects, a low liability for adverse weight and metabolic effects, and no effect on prolactin levels. Additional studies are needed to further confirm the long-term efficacy and safety of ulotaront.
Subject terms: Schizophrenia, Schizophrenia
Introduction
Ulotaront (SEP-363856), one of the first of a new class of CNS-active compounds, is an agonist at trace amine-associated receptor 1 (TAAR1) as well as serotonin 5-HT1A receptors. TAAR1 is a G-protein-coupled receptor expressed in cortical, limbic, and midbrain monoaminergic regions that modulate dopaminergic, serotonergic, and glutamatergic activity1–6. In contrast to first- and second-generation antipsychotics, the efficacy of ulotaront is not mediated by blockade of D2 or 5-HT2A receptors7. Ulotaront has demonstrated positive effects in rodent models assessing endophenotypes of schizophrenia, including phencyclidine (PCP)-induced hyperactivity, prepulse inhibition, and PCP-induced deficits in social interaction and cognition7,8. In addition, ulotaront has also been shown to reduce ketamine-induced increases in striatal dopamine synthesis capacity in mice, suggesting the potential to modulate presynaptic dopamine dysfunction observed in schizophrenia patients9.
Suppression of rapid eye movement sleep has also been reported after single doses of ulotaront in both rats and humans and was utilized as a translational pharmacodynamic measure to guide dose selection in subsequent clinical trials in schizophrenia patients10.
In a prior 4-week, randomized, double-blind, placebo-controlled clinical trial, ulotaront, in doses of 50 or 75 mg, demonstrated significant efficacy in the short-term treatment of adults with an acute exacerbation of schizophrenia11. The study found ulotaront to have a safety and tolerability profile that appeared to differ from the profile exhibited by antipsychotic agents acting via D2/5-HT2A receptor binding mechanism described in the literature, including the absence of clinically meaningful effects on prolactin, extrapyramidal symptom (EPS) related adverse effects, and low liability for adverse weight and metabolic effects. While this is placebo-controlled trial lacked an active (D2 antagonist) comparator, the absence of ESP-related events and the absence of prolactin effects were notable.
We report here the results of the 26-week, open-label extension phase study (ClinicalTrials.gov Identifier: NCT02970929) for patients who completed the initial 4-week study11. This open-label study was designed to evaluate the long-term safety, tolerability, and effectiveness of ulotaront in patients with schizophrenia.
Results
A total of 193 patients completed the 4-week, double-blind, placebo-controlled trial, of whom 157 patients (81.3%) provided informed consent and continued into the open-label extension study, including 78 patients initially randomized to double-blind ulotaront (and who continued on ulotaront in the open-label extension study) and 79 patients randomized to double-blind placebo (who were switched to ulotaront at entry into the open-label extension study; Fig. 1). Switching was accomplished while maintaining the double-blind of the initial 4-week trial. One patient discontinued from the extension study without receiving a dose of study medication and was excluded from all safety and efficacy analyses.
Fig. 1. Patient disposition.
Completion rates and categorization of reasons for discontinuation during 26 weeks of open-label treatment with ulotaront.
Demographic and clinical characteristics at the extension phase baseline are summarized in Table 1. A total of 105 patients (66.9%) completed 26 weeks of open-label treatment. The Kaplan–Meier estimate of median time to discontinuation from open-label treatment is >26 weeks (Fig. 2). For the combined sample, reasons for premature discontinuation were adverse events (n = 18; 11.5%; 16 due to worsening of schizophrenia or psychosis), lack of efficacy (n = 8; 5.1%), patient withdrawal (n = 16; 10.2%), and miscellaneous other reasons (n = 10; 6.4%; Fig. 1).
Table 1.
Characteristics of patients at open-label baseline (safety population).
| Characteristic | DB-placebo → OL-ulotaront (N = 79) | DB-ulotaront → OL-ulotaront (N = 77)b |
|---|---|---|
| Male, n (%) | 50 (63.3) | 52 (67.5) |
| Agea, years, mean (SD) | 30.2 (6.4) | 30.2 (5.7) |
| Race, n (%) | ||
| White | 73 (92.4) | 63 (81.8) |
| Black | 5 (6.3) | 10 (13.0) |
| Other | 1 (1.3) | 4 (5.2) |
| Hispanic, n (%) | 4 (5.1) | 1 (1.3) |
| Body mass index, kg/m2, mean (SD) | 24.3 (3.2) | 25.9 (4.3) |
| Time since initial onset of schizophreniaa, years, mean (SD) | 4.3 (4.0) | 5.2 (4.6) |
| Prior psychiatric hospitalizationsa | ||
| Mean (SD) | 1.2 (0.8) | 1.3 (0.7) |
| None, n (%) | 18 (22.8) | 11 (14.3) |
DB double-blind, OL open-label.
aAge, time since initial onset of schizophrenia, and number of prior psychiatric hospitalizations are calculated at entry into the initial double-blind study.
bOne patient discontinued without receiving a dose of study medication and was excluded from all safety and efficacy analyses.
Fig. 2. Kaplan–Meier estimate.
Comparison of the probability of staying in the study during 26 weeks of open-label treatment for the two ulotaront subgroups.
Modal daily doses of ulotaront utilized during extension phase treatment were 25 mg/d (1.9% of patients), 50 mg/d (42.9%), and 75 mg/d (54.5%). Most patients (91.7%) met medication adherence criteria, based on pill counts and defined as taking 75–125% of prescribed doses during the study. In the safety population, the most frequently reported concomitant medications were anxiolytics (15.4%), hypnotics/sedatives (7.1%), and analgesics/antipyretics (7.1%).
Effectiveness
Table 2 summarizes the effect of open-label extension phase treatment for the combined patient sample, and separately for double-blind ulotaront and double-blind placebo patients. On the Positive and Negative Syndrome Scale (PANSS) total score, mean (95% CI) observed change from open-label baseline to week 26 for double-blind ulotaront, double-blind placebo, and combined patients, respectively, was −17.1 (−20.6, −13.6), −27.9 (−32.5, −23.4), and −22.6 (−25.6, −19.6) (Table 2).
Table 2.
Mean (SD) change from double-blind and open-label baselines to week 26 in efficacy measures by double-blind treatment assignment.
| Efficacy measure | n | DB baseline mean (SD) | n | OL baseline mean (SD) | n | Mean (SD) change from DB baseline (OC) | n | Mean (SD) change from OL baseline (OC) | 95% CI (effect size) for change from OL baseline (OC)a | n | Mean (SD) change from OL baseline (LOCF) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PANSS total score | |||||||||||
| All extension phase patients | 156 | 101.5 (8.0) | 156 | 83.1 (15.0) | 104 | −41.8 (14.0) | 104 | −22.6 (15.5) | −25.6, −19.6 (1.46) | 155 | −13.8 (21.6) |
| DB-PBO to ulotaront | 79 | 100.4 (7.7) | 79 | 86.3 (13.4) | 53 | −41.2 (14.6) | 53 | −27.9 (16.4) | −32.5, −23.4 (1.70) | 78 | −17.2 (24.7) |
| DB-ulotaront to ulotaront | 77 | 102.6 (8.2) | 77 | 80.0 (16.0) | 51 | −42.4 (13.4) | 51 | −17.1 (12.3) | −20.6, −13.6 (1.39) | 77 | −10.3 (17.3) |
| PANSS positive symptom | |||||||||||
| All extension phase patients | 156 | 25.7 (3.2) | 156 | 19.8 (5.0) | 104 | −13.5 (4.7) | 104 | −7.3 (5.4) | −8.3, −6.2 (1.36) | 155 | −4.5 (7.0) |
| DB-PBO to ulotaront | 79 | 25.5 (3.2) | 79 | 20.7 (4.7) | 53 | −13.4 (4.8) | 53 | −8.7 (5.7) | −10.2, −7.1 (1.53) | 78 | −5.6 (7.6) |
| DB-ulotaront to ulotaront | 77 | 25.9 (3.3) | 77 | 18.9 (5.1) | 51 | −13.5 (4.8) | 51 | −5.8 (4.7) | −7.2, −4.5 (1.25) | 77 | −3.3 (6.3) |
| PANSS negative symptom | |||||||||||
| All extension phase patients | 156 | 25.4 (4.0) | 156 | 22.3 (4.4) | 104 | −8.4 (4.5) | 104 | −5.2 (4.2) | −6.0, −4.4 (1.24) | 155 | −3.5 (4.9) |
| DB-PBO to ulotaront | 79 | 25.5 (4.2) | 79 | 23.1 (4.2) | 53 | −8.5 (5.0) | 53 | −6.4 (4.6) | −7.6, −5.1 (1.38) | 78 | −4.1 (5.8) |
| DB-ulotaront to ulotaront | 77 | 25.2 (3.9) | 77 | 21.4 (4.4) | 51 | −8.3 (4.0) | 51 | −4.0 (3.4) | −4.9, −3.1 (1.19) | 77 | −2.9 (3.7) |
| PANSS general psychopathology | |||||||||||
| All extension phase patients | 156 | 50.4 (5.0) | 156 | 41.1 (7.9) | 104 | −19.9 (7.9) | 104 | −10.2 (8.3) | −11.8, −8.5 (1.22) | 155 | −5.8 (11.4) |
| DB-PBO to ulotaront | 79 | 49.3 (5.0) | 79 | 42.5 (7.0) | 53 | −19.2 (8.4) | 53 | −12.9 (9.1) | −15.4, −10.4 (1.43) | 78 | −7.5 (13.1) |
| DB-ulotaront to ulotaront | 77 | 51.5 (4.8) | 77 | 39.6 (8.6) | 51 | −20.7 (7.3) | 51 | −7.3 (6.4) | −9.1, −5.5 (1.14) | 77 | −4.1 (9.2) |
| CGI-Severity score | |||||||||||
| All extension phase patients | 156 | 5.0 (0.4) | 156 | 4.0 (0.8) | 104 | −2.0 (0.8) | 104 | −1.0 (0.9) | −1.2, −0.8 (1.07) | 155 | −0.6 (1.2) |
| DB-PBO to ulotaront | 79 | 4.9 (0.4) | 79 | 4.2 (0.7) | 53 | −2.1 (0.8) | 53 | −1.4 (0.9) | −1.7, −1.1 (1.51) | 78 | −0.9 (1.3) |
| DB-ulotaront to ulotaront | 77 | 5.0 (0.4) | 77 | 3.8 (0.9) | 51 | −1.8 (0.8) | 51 | −0.5 (0.7) | −0.7, −0.4 (0.82) | 77 | −0.3 (0.9) |
| BNSS total score | |||||||||||
| All extension phase patients | 148 | 38.4 (11.9) | 150 | 33.0 (11.4) | 96 | −16.8 (12.4) | 100 | −11.3 (9.7) | −13.2, −9.3 (1.16) | 149 | −8.0 (11.2) |
| DB-PBO to ulotaront | 76 | 38.3 (12.8) | 77 | 34.6 (11.4) | 50 | −17.8 (13.5) | 51 | −14.4 (9.8) | −17.2, −11.7 (1.47) | 76 | −9.6 (12.7) |
| DB-ulotaront to ulotaront | 72 | 38.5 (11.0) | 73 | 31.4 (11.3) | 46 | −15.7 (11.2) | 49 | −8.0 (8.5) | −10.4, −5.6 (0.94) | 73 | −6.3 (9.1) |
| UPSM PANSS NAA | |||||||||||
| All extension phase patients | 156 | 2.6 (0.7) | 156 | 2.3 (0.7) | 104 | −0.7 (0.8) | 104 | −0.4 (0.7) | −0.6, −0.3 (0.63) | 155 | −0.3 (0.7) |
| DB-PBO to ulotaront | 79 | 2.6 (0.8) | 79 | 2.4 (0.7) | 53 | −0.8 (0.9) | 53 | −0.6 (0.8) | −0.8, −0.4 (0.77) | 78 | −0.4 (0.8) |
| DB-ulotaront to ulotaront | 77 | 2.5 (0.6) | 77 | 2.2 (0.7) | 51 | −0.7 (0.7) | 51 | −0.3 (0.6) | −0.5, −0.1 (0.47) | 77 | −0.2 (0.6) |
| UPSM PANSS NDE | |||||||||||
| All extension phase patients | 156 | 2.1 (0.8) | 156 | 1.9 (0.7) | 104 | −0.7 (0.8) | 104 | −0.5 (0.7) | −0.6, −0.3 (0.66) | 155 | −0.3 (0.7) |
| DB-PBO to ulotaront | 79 | 2.1 (0.8) | 79 | 2.0 (0.6) | 53 | −0.7 (0.9) | 53 | −0.6 (0.8) | −0.8, −0.4 (0.79) | 78 | −0.4 (0.8) |
| DB-ulotaront to ulotaront | 77 | 2.2 (0.7) | 77 | 1.9 (0.7) | 51 | −0.7 (0.7) | 51 | −0.3 (0.6) | −0.5, −0.1 (0.54) | 77 | −0.3 (0.7) |
| MADRS total score | |||||||||||
| All extension phase patients | 156 | 12.6 (7.2) | 156 | 9.2 (6.3) | 104 | −8.1 (6.4) | 104 | −4.5 (5.3) | −5.6, −3.5 (0.86) | 155 | −2.2 (7.3) |
| DB-PBO to ulotaront | 79 | 12.5 (7.3) | 79 | 9.6 (6.2) | 53 | −8.2 (6.9) | 53 | −5.5 (6.1) | −7.2, −3.8 (0.90) | 78 | −2.9 (8.7) |
| DB-ulotaront to ulotaront | 77 | 12.8 (7.2) | 77 | 8.7 (6.5) | 51 | −8.0 (5.9) | 51 | −3.5 (4.0) | −4.6, −2.4 (0.87) | 77 | −1.5 (5.6) |
| UPSA-B total score | |||||||||||
| All extension phase patients | 156 | 75.9 (16.5) | 113 | +6.8 (11.5) | 4.6, 8.9 (0.59) | 134 | +6.2 (11.6) | ||||
| DB-PBO to ulotaront | 79 | 75.8 (16.2) | 58 | +8.6 (13.2) | 5.1, 12.0 (0.65) | 67 | +8.3 (12.8) | ||||
| DB-ulotaront to ulotaront | 77 | 76.0 (16.9) | 55 | +4.9 (9.1) | 2.4, 7.3 (0.53) | 67 | +4.1 (9.9) | ||||
DB double-blind, OL open-label, OC observed case, LOCF last observation carried forward, PBO placebo, CI confidence interval, SD standard deviation, PANSS Positive and Negative Syndrome Scale, CGI clinical global impression, BNSS Brief Negative Symptom Scale, UPSA-B UCSD Performance-Based Skills Assessment-Brief Version, MADRS Montgomery–Åsberg Depression Rating Scale, UPSM uncorrelated PANSS score matrix, NAA negative apathy/avolition factor, NDD negative-deficit of expression factor.
a95% Confidence interval and within-group effect size shown for change from open-label baseline to week 26.
On the Clinical Global Impression, Severity (CGI-S) score, mean (95% CI) observed change from open-label baseline to week 26 was −0.5 (−0.7, −0.4) for double-blind ulotaront patients and −1.4 (−1.7, −1.1) for double-blind placebo patients (Table 2). A similar pattern of mean changes in symptom severity measures, from open-label baseline to week 26, was evident in double-blind ulotaront and double-blind placebo patients, respectively, for the PANSS positive subscale (−5.8 and −8.7), the PANSS negative subscale (−4.0 and −6.4), the PANSS general psychopathology subscale (−7.3 and −12.9), Brief Negative Symptom Scale (BNSS) total score (−8.0 and −14.4), uncorrelated PANSS score matrix (UPSM) Negative Apathy/Avolition Factor (NAA) score (−0.3 and −0.6), and the UPSM Negative-Deficit of Expression Factor (NDE) score (−0.3 and −0.6).
For double-blind ulotaront patients, both the PANSS total (Table 2 and Fig. 3A) and subscale scores (Table 2 and Fig. 3B) showed continued improvement during open-label treatment. Mean change from double-blind baseline to open-label baseline in PANSS total score was −22.6; and mean changes from double-blind baseline to open-label weeks 4, 12, 20 and 26 were −34.1, −36.3, −37.4, and −42.4, respectively.
Fig. 3. Mean change from double-blind baseline during 4 weeks of double-blind treatment with ulotaront or placebo and 26 weeks of open-label treatment with ulotaront.
A Change in PANSS total score: observed case analysis. B Change in PANSS subscale scores: observed case analysis.
Treatment response rates (≥30% reduction in PANSS total score from double-blind baseline) for double-blind ulotaront and double-blind placebo patients, respectively, were 94.1% and 92.5% at week 26 (observed case), and 74.0% and 73.1% at LOCF-endpoint; and response rates (≥50% reduction in PANSS) were 76.5% and 67.9% at week 26 (observed case) and 54.5% and 48.7% at LOCF-endpoint.
Depressive symptoms, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS) total score, were mostly in the mild-to-moderate severity range at double-blind baseline (double-blind baseline mean for all extension phase patients, 12.6). The mean observed change from open-label baseline to week 26 for double-blind ulotaront and double-blind placebo patients, respectively, was −3.5 and −5.5 (Table 2). Observed improvement at week 26 was also evident on the University of California, San Diego, Performance-Based Skills Assessment-Brief version (UPSA-B) for double-blind ulotaront and double-blind placebo patients, respectively: mean change from open-label baseline +4.9 and +8.6, with a mean UPSA-B total score of 84 at week 26 for all extension phase patients combined.
Among the 51 patients initially randomized to double-blind ulotaront, and who achieved a clinical response after receiving 4 weeks of treatment, the Kaplan–Meier estimate (95% CI) of the probability of relapse at the end of the open-label extension treatment period was 0.23 (0.13, 0.38).
Safety
In the open-label extension study, the overall incidence of AEs was 56.4%; 4 AEs occurred with an incidence ≥5% among all extension phase patients: schizophrenia (12.2%), headache (11.5%), insomnia (8.3%), and anxiety (5.1%; Table 3). The majority of AEs were either mild or moderate in severity, with 5.1% of patients reporting a severe AE. The only severe AE reported by more than one patient was schizophrenia (n = 5; 3.2%). A small improvement in sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI) global score, was observed at week 26 (mean [SD] change from open-label baseline −2.0 [3.0]).
Table 3.
Incidence of treatment-emergent adverse events (safety population).
| Safety parameter, n (%) | OL-ulotaronta (N = 156) |
|---|---|
| Schizophrenia | 19 (12.2) |
| Headache | 18 (11.5) |
| Insomnia | 13 (8.3) |
| Anxiety | 8 (5.1) |
| Somnolence | 7 (4.5) |
| Nasopharyngitis | 7 (4.5) |
| Nausea | 6 (3.8) |
| Irritability | 5 (3.2) |
| Influenza | 5 (3.2) |
| Weight decreased | 5 (3.2) |
| Prolactin increased | 4 (2.6) |
| Extrapyramidal adverse events, any | 5 (3.2) |
| Parkinsonism | 2 (1.3) |
| Dyskinesia | 1 (0.6) |
| Tremor | 1 (0.6) |
| Restlessness | 1 (0.6) |
| At least one adverse event | 88 (56.4) |
| Adverse events rated as “severe” | 8 (5.1) |
Individual adverse events with an incidence ≥2% are shown (except for extrapyramidal adverse events).
OL open-label.
aAll extension phase patients.
The incidence of AEs associated with EPS was low (n = 5; 3.2%; Table 3). Movement disorder scales showed no clinically meaningful changes from open-label baseline to week 26 (observed case): mean (SD) changes in the Simpson–Angus Scale (SAS) mean score, Barnes Rating Scale for Drug-Induced Akathisia (BARS) total score, and the Abnormal Involuntary Movement Scale (AIMS) total score were −0.0 (0.1), −0.1 (0.2), and 0.0 (0.1), respectively.
There were no deaths during the study. Suicidal ideation, assessed by the Columbia–Suicide Severity Rating Scale (C-SSRS), occurred in 3 patients, one of whom also reported suicidal behavior (aborted attempt on day 23; an adverse event of suicidal ideation started on day 18, study drug was discontinued on day 19, and the event resolved on day 30). Fifteen patients experienced a serious adverse event (SAE) of whom 12 reported an SAE of schizophrenia/psychotic disorder, one patient reported suicidal ideation and acute psychosis, one patient reported depression, and one had a uterine hemorrhage (unrelated to study drug).
Up to 26 weeks of open-label treatment with ulotaront was associated with minimal changes in body weight (mean observed change from double-blind baseline to week 26, −0.3 kg) or body mass index (−0.1 kg/m2; Table 4). The percent of patients with ≥7% increase or decrease in weight from open-label baseline to the LOCF-endpoint was 1.3% and 5.2%, respectively. No noteworthy changes were observed in metabolic laboratory parameters, including total cholesterol (median change from double-blind baseline to week 26, −2.0 mg/dL), triglycerides (−5.0 mg/dL), glucose (+2.0 mg/dL), or HbA1c (0.0%; Table 4). Treatment with ulotaront had no clinically meaningful effect on serum prolactin levels in either female (median change at week 26, −3.4 ng/mL) or males (−2.7 ng/mL; Table 4).
Table 4.
Double-blind baseline values and change at week 26 in weight, body mass index, metabolic parameters, and prolactin (safety population; observed case analysis).
| Safety parameter | Double-blind baseline | Week 26 | ||
|---|---|---|---|---|
| N | Ulotaront | N | Ulotaront | |
| Weight, kg, mean (SD) | 156 | 75.4 (13.9) | 104 | −0.3 (3.7) |
| Body mass index, kg/m2, mean (SD) | 156 | 25.1 (3.9) | 104 | −0.1 (1.2) |
| Total cholesterol, mg/dL, median | 156 | 174.5 | 111 | −2.0 |
| LDL cholesterol, mg/dL, median | 156 | 101.5 | 111 | −9.0 |
| HDL cholesterol, mg/dL, median | 156 | 48.0 | 111 | 0.0 |
| Triglycerides, mg/dL, median | 156 | 101.0 | 111 | −5.0 |
| Glucose, mg/dL, median | 156 | 92.0 | 109 | +2.0 |
| HbA1c, %, median | 155 | 5.2 | 109 | 0.0 |
| Prolactin, ng/mL, median | ||||
| Female | 54 | 16.1 | 39 | −3.4 |
| Male | 102 | 11.6 | 73 | −2.7 |
Lipid and glucose data are shown for total available patients at week 26; 96.4% (107/111) of lipid results were fasted at week 26, 96.3% (105/109) of glucose results were fasted at week 26.
Ulotaront data are shown for all extension phase patients; mean baseline and change values are shown for weight and BMI; median baseline and change values are shown for laboratory parameters.
HDL high-density lipoprotein, LDL low-density lipoprotein.
Few clinically meaningful changes in vital signs occurred during 26 weeks of extension phase treatment. Eight patients (5.2%) met predefined criteria for orthostatic hypotension (decreased systolic blood pressure by ≥20 mmHg or decreased diastolic blood pressure by ≥10 mmHg) and 4 patients (2.6%) met criteria for orthostatic tachycardia (increase in heart rate by ≥20 beats per minute and heart rate >100 beats per minute). No AEs related to orthostatic hypotension or orthostatic tachycardia were reported. Overall, mean changes from open-label baseline in electrocardiogram parameters were small and not clinically meaningful. No patient had a QTcF interval ≥480 msec at any time point during the 26-week extension phase; one patient had an increase in QTcF interval from open-label baseline by ≥60 msec.
Discussion
We report here the results of a multi-regional, open-label study of the safety and effectiveness of 26 weeks of flexible-dose treatment with ulotaront (25, 50, or 75 mg/d) in adults with schizophrenia who had completed an initial 4-week, double-blind, placebo-controlled study11. Long-term treatment with ulotaront, a TAAR1 and 5-HT1A receptor agonist, was characterized by an adverse event profile consistent with its non-D2 receptor binding mechanism of action. Notably, ulotaront was not associated with clinically meaningful changes in prolactin levels or in movement disorder scales (SAS, BARS, AIMS); and the incidence of Parkinson-like symptoms and akathisia were low. In addition, treatment with ulotaront was not associated with clinically meaningful effects on weight or metabolic parameters or increase in QTc interval. Three serious adverse events were reported that were not related to the underlying diagnosis of schizophrenia (suicidal ideation, depression, uterine hemorrhage). Overall, adverse event rates were low, with few events (5.1%) rated as severe. These long-term findings extend the tolerability results of the initial 4-week, double-blind study in which ulotaront was found to have a low (<7%) incidence of individual adverse events (for events that occurred more frequently in the ulotaront group), with each event minimally different from placebo (NNH ≥ 40)11. Taken together, the safety findings from the prior short-term11 and current long-term extension study suggest that ulotaront represents a well-tolerated treatment option for patients with schizophrenia.
The study completion rate after 26 weeks of open-label treatment with ulotaront (67%) was relatively high compared to 26-week completion rates of 39–65% reported previously in other long-term studies of atypical antipsychotics12–14. Estimated discontinuation rates at 6 months (based on KM plots) from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study13 provide a useful benchmark for comparison with the current results given the “real world” features of the study. Olanzapine had the highest 6-month completion rate (55%), while rates were notably lower for risperidone (43%), perphenazine (41%), quetiapine (39%), and ziprasidone (38%). Medication discontinuation during maintenance therapy with antipsychotics has been shown to significantly increase rates of schizophrenia relapse and rehospitalization15,16. It is possible that the overall tolerability and safety of ulotaront observed in the current long-term, open-label study contributed to the relatively low rates of discontinuation over the treatment period.
In the current study, treatment with ulotaront was associated with small reductions in weight, total and LDL cholesterol, and triglycerides, and a small increase in glucose but no change in glycosylated hemoglobin. The low propensity of ulotaront for treatment-related increases in weight and metabolic parameters is especially important given the need for long-term treatment in patients with schizophrenia. Patients with a diagnosis of schizophrenia are an at-risk population with a marked increase in cardiovascular mortality, and a life expectancy 15–20 years shorter than in the general population17,18. Maintenance therapy with selected atypical antipsychotics is associated with a significant increase in weight and metabolic risk factors17,18. Given these findings, the overall safety profile of ulotaront, including a lack of clinically meaningful metabolic effects and movement disorder symptoms, appears distinguished from currently available treatment options.
During the initial double-blind study, the magnitude of improvement in PANSS total score observed was comparable to the improvement reported for atypical antipsychotics acting via D2 receptor blockade19–24. During long-term treatment with ulotaront, continued improvement was observed across a broad array of schizophrenia symptom measures, including PANSS positive, negative, and general psychopathology subscales. Improvement in PANSS total score appeared to persist throughout the 26-week, open-label study including over the last 6 weeks of treatment. These results are consistent with pre-clinical findings indicating the potential for antipsychotic activity associated with ulotaront7, and suggest that the mechanism of action of ulotaront, involving TAAR1 agonism, represents a potentially effective approach to the treatment of patients with schizophrenia. Specifically, the results of this long-term study indicate that ulotaront treatment was associated with sustained improvement in psychotic symptoms in patients with schizophrenia.
During extension phase treatment ulotaront was associated with continued improvement in depressive symptoms as measured by the MADRS. Clinically significant depressive symptoms occur in approximately 25% of patients and represent an important treatment consideration since the presence of depressive symptoms is associated with poorer functioning, quality of life, and treatment adherence25–27. The mean MADRS score for all extension phase patients at double-blind baseline was 12.6, indicating mild-to-moderate levels of depressive symptomatology in most patients. By week 26, the mean MADRS score for all patients was <5, consistent with an absence of clinically meaningful depressive symptomatology.
Study limitations include an open-label, uncontrolled design for the extension study, and enrollment limited to patients ≤40 years at entry into the initial double-blind trial11. Furthermore, patients initially randomized to ulotaront in the double-blind portion of the study more likely continued in the open-label extension phase if they derived benefit from and tolerated ulotaront. However, 50.3% of the sample consisted of patients originally randomized to placebo who had an unknown response and tolerability to ulotaront, mitigating a potential selection bias that might otherwise have affected the results.
In conclusion, in this open-label extension study, ulotaront, one of the first of a new class of TAAR1 agonists, in the daily dose range of 25–75 mg, was generally safe, well-tolerated, and effective in the long-term treatment of patients with schizophrenia. Treatment with ulotaront over a 6-month study period was characterized by relatively high completion rates, an adverse event profile that was notable for the low rate of extrapyramidal-related adverse effects, a low liability for adverse weight, and metabolic effects, and no effect on prolactin levels. Additional studies are needed to further confirm the long-term efficacy and safety of ulotaront.
Methods
This was a multi-regional, open-label extension study (consisting of 26 weeks of open-label treatment with ulotaront plus 1 week of follow-up off study drug) designed to evaluate the long-term safety, tolerability, and effectiveness of ulotaront for the treatment of adults with schizophrenia who completed the previously reported 4-week double-blind, placebo-controlled study (NCT # NCT02969382)11. Entry into the preceding acute study was limited to patients 18 to 40 years of age who met DSM-5 criteria for schizophrenia28 for at least 6 months with a Positive and Negative Syndrome Scale29 (PANSS) total score ≥80 (for more details see Koblan and colleagues11).
The study was conducted from January 2017 to January 2019 at 32 clinical sites in 5 countries (Hungary, Romania, Russia, Ukraine, and the United States). The study was approved by an Institutional Review Board/ethics committee at each investigational site and was conducted in accordance with the International Conference on Harmonisation Good Clinical Practices guidelines and with the ethical principles of the Declaration of Helsinki. After a full explanation of the study was provided, written informed consent was obtained from all patients.
Patients who met entry criteria were transitioned directly from the acute study, with the final week 4 visit of the acute study serving as the baseline visit of the current open-label study. Hospitalization was permitted during the first week of the current study, if deemed appropriate by the Investigator. To maintain the double-blind of the initial 4-week trial, patients enrolled in the current extension study received a starting ulotaront dose of 50 mg/d for 3 days, regardless of their initial double-blind treatment assignment (ulotaront or placebo). Beginning on day 4, up-titration to 75 mg/d was permitted but not required. From the week 1 visit, flexible doing from 25 to 75 mg/d was permitted. Changes in dose were made in increments/decrements of 25 mg.
Patients were assessed at weekly intervals for the first 4 weeks and then every 4 weeks thereafter up to week 24; a final end-of-treatment assessment was performed at week 26, and a follow-up visit at week 27. Safety assessments included monitoring for adverse events (AEs) and serious adverse events (SAEs), evaluation of vital signs and weight, body mass index, waist circumference, laboratory tests (including fasting lipid and glucose levels), and 12-lead electrocardiography. Extrapyramidal symptoms (EPS) were assessed by the Simpson–Angus Scale30 (SAS), the Barnes Rating Scale for Drug-Induced Akathisia31 (BARS), and the Abnormal Involuntary Movement Scale32 (AIMS). Suicidality was assessed by the Columbia–Suicide Severity Rating Scale33 (C-SSRS). Sleep quality was assessed by the Pittsburgh Sleep Quality Index34 (PSQI).
Effectiveness was assessed by the PANSS total and subscale scores, the Clinical Global Impression, Severity32 (CGI-S) scale, the Brief Negative Symptom Scale35 (BNSS), the Montgomery-Åsberg Depression Rating Scale (MADRS)36, and the University of California, San Diego, Performance-Based Skills Assessment-Brief version (UPSA-B)37. Effectiveness was also assessed using the uncorrelated PANSS score matrix (UPSM)-transformed PANSS factors which measure drug effects on clinical symptom domains of schizophrenia with greater specificity by correcting for correlated improvements among the individual PANSS items38.
Rate of relapse and time to relapse were evaluated during the 26-week open-label treatment period for patients who demonstrated a clinical response to 4 weeks of treatment with ulotaront in the double-blind phase. Clinical response was defined as ≥20% improvement in PANSS total score from double-blind baseline and CGI-S score ≤4. Relapse was defined as the earliest occurrence of any of the following: (1) ≥30% increase in PANSS total score from the PANSS score at the time of clinical response and a CGI-S score ≥ 3; (2) rehospitalization for worsening of psychosis; or (3) emergence of suicidality, homicidality, and/or risk of harm to self or others.
Statistical methods
The safety population consisted of all patients who were enrolled and received at least one dose of ulotaront. The safety analysis was primary and included assessment of the incidence of AEs, SAEs, and AEs leading to study discontinuation, summarized descriptively in terms of incidence, event count, and severity. Clinical laboratory tests and vital signs, body weight, body mass index, waist circumference, and 12-lead electrocardiograms were calculated for change from double-blind and open-label baselines and are summarized descriptively. The frequency and severity of suicidal ideation and suicidal behavior using the C-SSRS were also provided.
Descriptive statistics were calculated for change in PANSS total and subscale scores, PANSS UPSM factor scores, CGI-S score, BNSS total score, MADRS total score, and UPSA-B total score, including means, standard deviations, 95% confidence intervals (CI), and within-group effect sizes (mean open-label baseline to week 26 change score divided by the standard deviation of the change). Kaplan–Meier estimates of the median time to discontinuation from the 26 weeks of open-label treatment were calculated for double-blind ulotaront patients and double-blind placebo patients. In the group of patients meeting clinical response criteria, Kaplan–Meier estimates of the probability of relapse were calculated for double-blind ulotaront patients at day 187 (counting from the clinical response), and for double-blind placebo patients at day 159 (counting from the clinical response).
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
This study was supported by funding from Sunovion Pharmaceuticals Inc. Sunovion discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube® platform and associated artificial intelligence algorithms.
Author contributions
C.U.C.: conception/design, data interpretation, manuscript drafting and revising, final manuscript approval, and accountability for all aspects of work. K.S.K.: conception/design, data interpretation, manuscript drafting and revising; final manuscript approval and accountability for all aspects of work. S.C.H.: conception/design, data interpretation, manuscript drafting and revising; final manuscript approval and accountability for all aspects of work. Y.L.: analysis, data interpretation, manuscript drafting and revising; final manuscript approval and accountability for all aspects of work. H.D.: conception/design, data interpretation, manuscript drafting and revising; final manuscript approval and accountability for all aspects of work. R.G.: conception/design, data interpretation, manuscript drafting and revising; final manuscript approval and accountability for all aspects of work. A.L.: conception/design, data interpretation, manuscript drafting and revising; final manuscript approval and accountability for all aspects of work.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Data availability
Sunovion Pharmaceuticals Inc. is part of a clinical trial data-sharing consortium that facilitates access for qualified researchers to selected anonymized clinical trial data. For up-to-date information on data availability please visit https://www.clinicalstudydatarequest.com and click on Sunovion.
Competing interests
Dr. Correll has been a consultant and/or advisor to or have received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. Drs. Koblan, Hopkins, Li, Dworak, Goldman, and Loebel are employees of Sunovion Pharmaceuticals Inc. Medical writing support was provided by Edward Schweizer, MD of Paladin Consulting Group, and was funded by Sunovion Pharmaceuticals Inc.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
The online version contains supplementary material available at 10.1038/s41537-021-00190-z.
References
- 1.Wolinsky TD, et al. The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes. Brain. Behav. 2007;6:628–639. doi: 10.1111/j.1601-183X.2006.00292.x. [DOI] [PubMed] [Google Scholar]
- 2.Lindemann L, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J. Pharmacol. Exp. Ther. 2008;324:948–956. doi: 10.1124/jpet.107.132647. [DOI] [PubMed] [Google Scholar]
- 3.Bradaia A, et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl Acad. Sci. USA. 2009;106:20081–20086. doi: 10.1073/pnas.0906522106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Revel FG, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl Acad. Sci. USA. 2011;108:8485–8490. doi: 10.1073/pnas.1103029108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Revel FG, et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry. 2012;72:934–942. doi: 10.1016/j.biopsych.2012.05.014. [DOI] [PubMed] [Google Scholar]
- 6.Revel FG, et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology. 2012;37:2580–2592. doi: 10.1038/npp.2012.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Dedic N, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J. Pharmacol. Exp. Ther. 2019;371:1–14. doi: 10.1124/jpet.119.260281. [DOI] [PubMed] [Google Scholar]
- 8.Begni V, et al. Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856. Int J. Mol. Sci. 2021;22:4119. doi: 10.3390/ijms22084119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kokkinou, M. et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol. Psychiatry10.1038/s41380-020-0740-6 (2020). [DOI] [PMC free article] [PubMed]
- 10.Hopkins SC, Dedic N, Koblan KS. Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans. Transl. Psychiatry. 2021;11:228. doi: 10.1038/s41398-021-01331-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Koblan KS, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N. Engl. J. Med. 2020;382:1497–1506. doi: 10.1056/NEJMoa1911772. [DOI] [PubMed] [Google Scholar]
- 12.Kasper S, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 2003;6:325–37. doi: 10.1017/S1461145703003651. [DOI] [PubMed] [Google Scholar]
- 13.Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223. doi: 10.1056/NEJMoa051688. [DOI] [PubMed] [Google Scholar]
- 14.Loebel A, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr. Res. 2013;147:95–102. doi: 10.1016/j.schres.2013.03.013. [DOI] [PubMed] [Google Scholar]
- 15.Leucht S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–2071. doi: 10.1016/S0140-6736(12)60239-6. [DOI] [PubMed] [Google Scholar]
- 16.De Hert M, et al. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs. 2015;29:637–658. doi: 10.1007/s40263-015-0269-4. [DOI] [PubMed] [Google Scholar]
- 17.Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat. Rev. Cardiol. 2021;18:136–145. doi: 10.1038/s41569-020-00463-7. [DOI] [PubMed] [Google Scholar]
- 18.Lemogne C, et al. Management of cardiovascular health in people with severe mental disorders. Curr. Cardiol. Rep. 2021;23:7. doi: 10.1007/s11886-020-01436-5. [DOI] [PubMed] [Google Scholar]
- 19.Correll CU, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–180. doi: 10.1002/wps.20420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Beasley CM, Jr., et al. Efficacy of olanzapine: an overview of pivotal clinical trials. J. Clin. Psychiatry. 1997;58:7–12. [PubMed] [Google Scholar]
- 21.Nakamura M, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2009;70:829–836. doi: 10.4088/JCP.08m04905. [DOI] [PubMed] [Google Scholar]
- 22.Ogasa M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology. 2013;225:519–30. doi: 10.1007/s00213-012-2838-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Potkin SG, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2003;60:681–690. doi: 10.1001/archpsyc.60.7.681. [DOI] [PubMed] [Google Scholar]
- 24.McEvoy JP, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J. Psychiatr. Res. 2007;41:895–905. doi: 10.1016/j.jpsychires.2007.05.002. [DOI] [PubMed] [Google Scholar]
- 25.Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009;35:383–402. doi: 10.1093/schbul/sbn135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am. J. Psychiatry. 2000;157:1379–1389. doi: 10.1176/appi.ajp.157.9.1379. [DOI] [PubMed] [Google Scholar]
- 27.Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr. Res. 2007;90:186–197. doi: 10.1016/j.schres.2006.09.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn DSM V (American Psychiatric Association, Washington, DC, 2013).
- 29.Kay SR, et al. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
- 30.Simpson GM, et al. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970;212:11–19. doi: 10.1111/j.1600-0447.1970.tb02066.x. [DOI] [PubMed] [Google Scholar]
- 31.Barnes TR. A rating scale for drug induced akathisia. Br. J. Psychiatry. 1989;154:672–676. doi: 10.1192/bjp.154.5.672. [DOI] [PubMed] [Google Scholar]
- 32.Guy, W. (ed.). ECDEU Assessment Manual for Psychopharmacology (Department of Health, Education, and Welfare, Rockville, MD, 1976).
- 33.Posner K, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry. 2011;168:1266–1277. doi: 10.1176/appi.ajp.2011.10111704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Buysse DJ, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213. doi: 10.1016/0165-1781(89)90047-4. [DOI] [PubMed] [Google Scholar]
- 35.Kirkpatrick B, et al. The Brief Negative Symptom Scale: psychometric properties. Schizophr. Bull. 2011;37:300–305. doi: 10.1093/schbul/sbq059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Montgomery SA, et al. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:382–389. doi: 10.1192/bjp.134.4.382. [DOI] [PubMed] [Google Scholar]
- 37.Mausbach BT, et al. Relationship of the brief UCSD performance-based skills assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disord. 2010;12:45–55. doi: 10.1111/j.1399-5618.2009.00787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Hopkins SC, Ogirala A, Loebel A, Koblan KS. Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. Schizophr. Bull. 2018;44:593–602. doi: 10.1093/schbul/sbx101. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Sunovion Pharmaceuticals Inc. is part of a clinical trial data-sharing consortium that facilitates access for qualified researchers to selected anonymized clinical trial data. For up-to-date information on data availability please visit https://www.clinicalstudydatarequest.com and click on Sunovion.